A platform approach to tackling AAV potency

AAV gene therapy products have complex mechanisms of action that pose unique challenges to potency assay development. Determining the true biological activity often requires multiple assays (i.e., a matrix approach), and the strategy for implementing these assays may evolve throughout the product lifecycle.

Join us as we discuss our strategy for potency assay development and how a platform approach can set you up for success.

• Hear about common challenges in AAV potency development
• What is a matrix approach?
• Learn about our platform methods that enable rapid development of phase-appropriate potency assays.

Aisleen McColl-Carboni

Senior Director, Analytical Development, Oxford Biomedica Solutions

Watch now

SPEAKERS

Aisleen McColl-Carboni

Senior Director, Analytical Development, Oxford Biomedica Solutions

You might also like

How to build an AAV platform that produces higher titers and percent full capsids

Leisha Kopp, Chris Brown

1 May

Watch

Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency

K Doucette, F Vass, K Bertram

25 July

Watch

Development of an automated AAV capsid titer assay on a high-throughput platform

Matthew J.Lotti, John Chappell

3 September

Watch

From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development

Audrey Chang, Joe Newcome

10 December

in 17

Days

Register

Integrated plasmid engineering and manufacturing process: a unified approach from lab to clinic

Pauline Vieugué, PhD, Philippe Ledent, PhD

24 April

Watch